A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.

  • Sparrow, Miles (Primary Chief Investigator (PCI))
  • McKenzie, Jo (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date29/01/24 → 28/01/26

Keywords

  • Clinical Trials
  • ABX464-107